AKRO FINAL DEADLINE: ROSEN, A LEADING LAW FIRM, Encourages Akero Therapeutics, Inc. Investors to Secure Counsel Before Important June 25 Deadline in Securities Class Action – AKRO

Core Points - Rosen Law Firm is reminding investors who purchased Akero Therapeutics, Inc. common stock between September 13, 2022, and October 9, 2023, of the June 25, 2024, lead plaintiff deadline for a class action lawsuit [1] - Investors may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1] - A class action lawsuit has already been filed, and interested parties must act by the specified deadline to serve as lead plaintiff [1] Case Details - The lawsuit alleges that Akero made false and misleading statements regarding the SYMMETRY study, which tested its lead product candidate, efruxifermin (EFX), in patients with Non-alcoholic Steatohepatitis (NASH) induced cirrhosis [3] - Key allegations include that approximately 20% of patients in the SYMMETRY study had cryptogenic cirrhosis and did not have definitive NASH at baseline [3] - The lawsuit claims that the results from these patients were improperly included in the study, which could materially influence the study's outcomes and increase the risk of failing to meet its primary endpoint [3] - It is also alleged that Akero did not align the study with U.S. FDA guidance, failing to rule out other potential causes of cirrhosis [3] - The misrepresentation of the SYMMETRY trial's nature and its implications for EFX's commercial viability is central to the claims made in the lawsuit [3]